IR@PKUHSC  > 北京大学第三临床医学院
学科主题临床医学
Efficacy and safety of telmisartan vs. losartan in control of mild-to-moderate hypertension: a multicentre, randomised, double-blind study
Zhu, JR1; Bai, J1; Cai, NS1; Tang, B1; Fan, WH1; Guo, JZ1; Ke, YN1; Guo, JX1; Sheng, LH1; Lu, ZY1; Cheng, NN1
关键词Telmisartan Losartan Angiotensin Ii Receptor Blocker Antihypertensives Hypertension
刊名INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
2004-12-01
suppl.145页:46-49
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Medicine, General & Internal ; Pharmacology & Pharmacy
研究领域[WOS]General & Internal Medicine ; Pharmacology & Pharmacy
关键词[WOS]II RECEPTOR BLOCKERS ; CARDIOVASCULAR EVENTS ; DOSE-RESPONSE ; CHINA ; ANTAGONIST
英文摘要

This multicentre, randomised, double-blind, double-dummy, parallel-group study compared the efficacy and safety of telmisartan with those of losartan after 8 weeks′ treatment. In total, 330 patients with mild-to-moderate hypertension (systolic blood pressure [SBP] <180 mmHg; diastolic blood pressure [DBP] 95-109 mmHg) were randomly assigned to receive once-daily treatment with telmisartan 40 mg (n = 164) or losartan 50 mg (n = 166). After 4 weeks′ treatment, if a patient′s DBP was greater than or equal to90 mmHg, the dose was increased to telmisartan 80 mg or losartan 100 mg, respectively. The results show that mean trough seated blood pressure was reduced significantly more in the telmisartan group than that in the losartan group (SBP 12.5 mmHg vs. 9.4 mmHg, p = 0.037; DBP 10.9 mmHg vs. 9.3 mmHg, p = 0.030). The overall DBP response rate (reduction from baseline in mean seated DBP greater than or equal to 10 mmHg and/or a mean seated DBP <90 mmHg) at the end of the study in the telmisartan group was higher than that in losartan group (70.1% vs. 58.7%, p = 0.020). At both the low and high doses, the DBP response rates for telmisartan were significantly higher than those for losartan (telmisartan 40 mg vs. losartan 50 mg: 46.3% vs. 32.5%, p = 0.010; telmisartan 80 mg vs. losartan 100 mg: 79.3% vs. 65.3%, p = 0.008). Adverse events with the two treatments were comparable (telmisartan vs. losartan 23.2% vs. 22.9%, p = 0.952). Most events were mild in intensity and abated within 72 h. Thus, telmisartan 40 mg or 80 mg administered once daily can reduce SBP and DBP effectively and safely.

语种英语
WOS记录号WOS:000225945300009
引用统计
被引频次:11[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/49909
专题北京大学第三临床医学院
作者单位1.Fu Dan Univ, Zhong Shan Hosp, Dept Med, Shanghai 200032, Peoples R China
2.Fu Dan Univ, Huashan Hosp, Shanghai, Peoples R China
3.Shanghai Med Univ 2, Ruijin Hosp, Shanghai, Peoples R China
4.Sino Japan Friendship Hosp, Beijing, Peoples R China
5.Beijing Univ, Affiliated Hosp 3, Beijing 100871, Peoples R China
6.Friendship Hosp, Beijing, Peoples R China
7.Cent China Univ Sci & Technol, Wuhan, Peoples R China
8.Fu Dan Univ, Dept Pharmacol, Shanghai, Peoples R China
推荐引用方式
GB/T 7714
Zhu, JR,Bai, J,Cai, NS,et al. Efficacy and safety of telmisartan vs. losartan in control of mild-to-moderate hypertension: a multicentre, randomised, double-blind study[J]. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE,2004,suppl.145:46-49.
APA Zhu, JR.,Bai, J.,Cai, NS.,Tang, B.,Fan, WH.,...&Cheng, NN.(2004).Efficacy and safety of telmisartan vs. losartan in control of mild-to-moderate hypertension: a multicentre, randomised, double-blind study.INTERNATIONAL JOURNAL OF CLINICAL PRACTICE,suppl.145,46-49.
MLA Zhu, JR,et al."Efficacy and safety of telmisartan vs. losartan in control of mild-to-moderate hypertension: a multicentre, randomised, double-blind study".INTERNATIONAL JOURNAL OF CLINICAL PRACTICE suppl.145(2004):46-49.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Zhu, JR]的文章
[Bai, J]的文章
[Cai, NS]的文章
百度学术
百度学术中相似的文章
[Zhu, JR]的文章
[Bai, J]的文章
[Cai, NS]的文章
必应学术
必应学术中相似的文章
[Zhu, JR]的文章
[Bai, J]的文章
[Cai, NS]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。